Predictive value of left ventricular ejection fraction in stem cell transplantation

被引:22
作者
Zangari, M
Henzlova, MJ
Ahmad, S
Scigliano, E
Isola, L
Platnik, J
Croft, LB
Sandler, D
Diamond, JA
Machac, J
Fruchtman, SM
机构
[1] Mt Sinai Sch Med, Dept Med, Div Hematol, New York, NY USA
[2] Mt Sinai Sch Med, Cardiovasc Inst, New York, NY USA
关键词
ejection; fraction; transplantation;
D O I
10.1038/sj.bmt.1701734
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We evaluated predictive value of left ventricular ejection fraction at rest (REF) and its increment with exercise (Delta EF) on autologous and allogeneic stem cell transplantation mortality. In a 7 year period, a total of 163 patients evaluated for stem cell transplantation were studied. All were followed for at least 3 months after the transplant. REF was discriminatory for peritransplant mortality only in younger (<43 years) patients (n = 66), particularly those who underwent autologous transplantation (n = 30), Resting ejection fraction was not a discriminator for early death in any other subgroup. Cardiac reserve (Delta EF) was significantly lower in patients (n = 35), who died early. The finding was most prominent in younger patients who underwent autologous transplantation (n = 26). Combination of decreased REF and low Delta EF (n = 18) was associated with high peritransplant mortality (56%), after both autologous and allogeneic transplantation. A low REF with an appropriate Delta EF (n = 43) was associated with a 19% peritransplant mortality and no deaths in the autologous group. These observations indicate that resting ejection fraction is of only limited value for pretransplant evaluation. However, measurement of cardiac reserve during exercise can provide important prognostic information before stem cell transplantation.
引用
收藏
页码:917 / 920
页数:4
相关论文
共 15 条
[1]  
BAELLO EB, 1986, CANCER TREAT REP, V70, P1187
[2]  
BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P173
[3]  
BRISTOW MR, 1978, CANCER TREAT REP, V62, P873
[4]  
CAZIN B, 1986, CANCER, V57, P2061, DOI 10.1002/1097-0142(19860515)57:10<2061::AID-CNCR2820571031>3.0.CO
[5]  
2-H
[6]   Doxorubicin-induced cardiomyopathy treated with carvedilol [J].
Fazio, S ;
Palmieri, EA ;
Ferravante, B ;
Bone, F ;
Biondi, B ;
Sacca, L .
CLINICAL CARDIOLOGY, 1998, 21 (10) :777-779
[7]  
GARDNER SF, 1993, BONE MARROW TRANSPL, V12, P139
[8]  
GOLDBERG MA, 1986, BLOOD, V68, P1114
[9]   CARDIOTOXICITY ASSOCIATED WITH HIGH-DOSE CYCLOPHOSPHAMIDE THERAPY [J].
GOTTDIENER, JS ;
APPELBAUM, FR ;
FERRANS, VJ ;
DEISSEROTH, A ;
ZIEGLER, J .
ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (06) :758-763
[10]   CARDIAC TOXICITY OF BONE-MARROW TRANSPLANTATION - PREDICTIVE VALUE OF CARDIOLOGIC EVALUATION BEFORE TRANSPLANT [J].
HERTENSTEIN, B ;
STEFANIC, M ;
SCHMEISER, T ;
SCHOLZ, M ;
GOLLER, V ;
CLAUSEN, M ;
BUNJES, D ;
WIESNETH, M ;
NOVOTNY, J ;
KOCHS, M ;
ADAM, WE ;
HEIMPEL, H ;
ARNOLD, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :998-1004